Literature DB >> 25382612

KIAA1549:BRAF fusion gene in pediatric brain tumors of various histogenesis.

Manila Antonelli1, Manuela Badiali, Loredana Moi, Francesca R Buttarelli, Caterina Baldi, Maura Massimino, Marc Sanson, Felice Giangaspero.   

Abstract

The KIAA1549:BRAF fusion gene is considered a driver genetic event in pilocytic astrocytoma. We investigated a series of 69 pediatric brain neoplasms of diverse histogenesis and grade using the RT-PCR and sequencing. We detected the KIAA1549:BRAF fusion gene in five of 34 non-PA tumors (14.7%), that is, one glioblastoma, one anaplastic astrocytoma, one anaplastic pleomorphic xanthoastrocytoma, 1 ependymoma, and 1 Atypical Teratoid Rhabdoid Tumor. Our study showed that the K-B, although uncommon, it can be detected in non-PA tumors of various histogenesis and grading.
© 2014 Wiley Periodicals, Inc.

Entities:  

Keywords:  BrafV600E; H3F3A mutation; KIAA1549:BRAF fusion gene; pediatric brain tumors; pediatric gliomas

Mesh:

Substances:

Year:  2014        PMID: 25382612     DOI: 10.1002/pbc.25272

Source DB:  PubMed          Journal:  Pediatr Blood Cancer        ISSN: 1545-5009            Impact factor:   3.167


  14 in total

1.  Pilocytic astrocytomas: BRAFV600E and BRAF fusion expression patterns in pediatric and adult age groups.

Authors:  Hetakshi Kurani; Mamta Gurav; Omshree Shetty; Girish Chinnaswamy; Aliasagar Moiyadi; Tejpal Gupta; Rakesh Jalali; Sridhar Epari
Journal:  Childs Nerv Syst       Date:  2019-07-18       Impact factor: 1.475

2.  A Comprehensive Method for Detecting Fusion Genes in Paediatric Brain Tumours.

Authors:  Akihide Kondo; Yuzaburo Shimizu; Satoshi Adachi; Ikuko Ogino; Mario Suzuki; Osamu Akiyama; Hajime Arai
Journal:  Cancer Genomics Proteomics       Date:  2018 Jul-Aug       Impact factor: 4.069

3.  Bevacizumab, irinotecan, temozolomide, tyrosine kinase inhibition, and MEK inhibition are effective against pleomorphic xanthoastrocytoma regardless of V600E status.

Authors:  Eric M Thompson; Daniel Landi; David Ashley; Stephen T Keir; Darell Bigner
Journal:  J Neurooncol       Date:  2018-08-17       Impact factor: 4.130

4.  Analysis of IDH1-R132 mutation, BRAF V600 mutation and KIAA1549-BRAF fusion transcript status in central nervous system tumors supports pediatric tumor classification.

Authors:  Midea Gierke; Jan Sperveslage; David Schwab; Rudi Beschorner; Martin Ebinger; Martin U Schuhmann; Jens Schittenhelm
Journal:  J Cancer Res Clin Oncol       Date:  2015-06-27       Impact factor: 4.553

Review 5.  Molecular Basis of Pediatric Brain Tumors.

Authors:  Alexia Klonou; Christina Piperi; Antonios N Gargalionis; Athanasios G Papavassiliou
Journal:  Neuromolecular Med       Date:  2017-07-26       Impact factor: 3.843

6.  Report of Canonical BCR-ABL1 Fusion in Glioblastoma.

Authors:  Ying Pang; Guangyang Yu; Madison Butler; Sivasish Sindiri; Young K Song; Jun S Wei; Xinyu Wen; Hisen-Chao Chou; Martha Quezado; Svetlana Pack; Liqiang Xi; Zied Abdullaev; Olga Kim; Alice Ranjan; Mythili Merchant; Ramya Antony; Lisa Boris; Orwa Aboud; David Kamson; Rosandra Kaplan; Megan Mackey; Kevin Camphausen; Kareem Zaghloul; Terri S Armstrong; Mark R Gilbert; Kenneth Aldape; Matthias Holdhoff; Javed Khan; Jing Wu
Journal:  JCO Precis Oncol       Date:  2021-08-25

7.  Novel BRAF gene fusions and activating point mutations in spindle cell sarcomas with histologic overlap with infantile fibrosarcoma.

Authors:  Alyssa J Penning; Alyaa Al-Ibraheemi; Michael Michal; Brandon T Larsen; Soo-Jin Cho; Christina M Lockwood; Vera A Paulson; Yajuan J Liu; Lukáš Plank; Karen Fritchie; Carol Beadling; Tanaya L Neff; Christopher L Corless; Erin R Rudzinski; Jessica L Davis
Journal:  Mod Pathol       Date:  2021-04-13       Impact factor: 8.209

Review 8.  Pilocytic astrocytoma: pathology, molecular mechanisms and markers.

Authors:  V Peter Collins; David T W Jones; Caterina Giannini
Journal:  Acta Neuropathol       Date:  2015-03-20       Impact factor: 17.088

Review 9.  Fusion genes as biomarkers in pediatric cancers: A review of the current state and applicability in diagnostics and personalized therapy.

Authors:  Neetha Nanoth Vellichirammal; Nagendra K Chaturvedi; Shantaram S Joshi; Donald W Coulter; Chittibabu Guda
Journal:  Cancer Lett       Date:  2020-11-25       Impact factor: 9.756

10.  MGMT Promoter Methylation and BRAF V600E Mutations Are Helpful Markers to Discriminate Pleomorphic Xanthoastrocytoma from Giant Cell Glioblastoma.

Authors:  Laura-Nanna Lohkamp; Maren Schinz; Claire Gehlhaar; Katrin Guse; Ulrich-Wilhelm Thomale; Peter Vajkoczy; Frank L Heppner; Arend Koch
Journal:  PLoS One       Date:  2016-06-02       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.